A batch of pharmaceutical companies have stopped production and revoked certificates!

Recently, the pharmaceutical market is still undergoing changes.
A large number of pharmaceutical company executives have resigned, and a number of pharmaceutical companies have stopped production, rectified or revoked their certificates
.
In this article, the author mainly sorts out the pharmaceutical companies that have discontinued production and revoked their certificates in the recent past
.
For example, on February 25, Guangyuyuan issued an announcement saying that Shanxi Guangyuyuan, a core holding subsidiary located in Taigu District, Jinzhong City, Shanxi Province, temporarily suspended work due to the impact of the local epidemic
.
It is reported that Shanxi Guangyuyuan currently has 103 "Guoyao Zhunzi" products in eight dosage forms, including pills, capsules and liquors, and the health food "Yuanzi Brand Guiling Jijiu".
The core products include Guilingji, Dingkun Dan et al
.
On February 22, the Jiangsu Provincial Food and Drug Administration issued an announcement on risk control measures for drug manufacturers (No.
1 of 2022)
.
The announcement shows that from November 28 to 30, 2021, after a follow-up inspection of the demon spirit at the end of Yangzhou, it was found that the company's hard capsules did not meet the relevant regulations on drug production quality management
.
According to relevant regulations, it was decided to suspend the production of hard capsules in this enterprise
.
It is reported that the company's business scope mainly includes the production of hard capsules, tablets and granules
.
At the end of January, the Guizhou Provincial Food and Drug Administration announced that Guizhou Shengjitang Pharmaceutical was ordered to immediately due to unannounced inspections (special inspections of Glimepiride tablets) found to have 2 serious defects, 2 major defects and other safety issues.
Suspension of the production and sales of glimepiride tablets
.
In addition, because this variety belongs to the second batch of domestically harvested varieties, the company's glimepiride tablets have also been disqualified from the selection by the National Federation, and the company will be suspended from January 29, 2022 to July 28, 2023.
Participation in the country Eligibility for declaration of centralized procurement activities
.
Judging from the reasons for the suspension of the above-mentioned pharmaceutical companies, the main reason is that the company was found to be defective, and some companies were also affected by the epidemic
.
For enterprises with defects, it is also necessary to strictly control the quality and safety, especially the enterprises that win the bid in centralized procurement, should pay more attention to the work of ensuring quality and quantity
.
In addition to the suspension of production, there are also a number of pharmaceutical companies that have recently cancelled their certificates
.
On February 22, the Shandong Provincial Food and Drug Administration announced that due to the expiration of the license validity period and the failure to re-issue the license, Weihai Renji Traditional Chinese Medicine Decoction Pieces Factory, Shandong Puhua Pharmaceutical Co.
, Ltd.
, and Shandong Lanjin Bioengineering Co.
, Ltd.
were announced by the provincial bureau.
, Shandong Taiyi Pharmaceutical Co.
, Ltd.
, Shandong Tianhua Pharmaceutical Co.
, Ltd.
, Shandong Liaocheng Luxi Pharmaceutical Excipients Co.
, Ltd.
, Liaocheng Luyun Pharmaceutical Empty Capsule Co.
, Ltd.
, Zibo Tianyuan Biotechnology Co.
, Ltd.
and other 21 companies were not in the publicity period.
Objection was raised, and the bureau cancelled the "drug production license" of the above-mentioned enterprises according to law
.
On January 21, the Gansu Provincial Food and Drug Administration announced plans to cancel Longxi Zhengyuan Pharmaceutical Co.
, Ltd.
, Longxi Pengfei Pharmaceutical Co.
, Ltd.
, Weiyuan County Pinzheng Pharmaceutical Co.
, Ltd.
, and Kangxian Sanhuang Traditional Chinese Medicine in Gansu Province.
Decoction Pieces Co.
, Ltd.
, Pingliang Xinyuan Traditional Chinese Medicine Piece Co.
, Ltd.
, Gansu Xiongxin Pharmaceutical Co.
, Ltd.
, Gannan Baicao Biotechnology Development Co.
, Ltd.
, Gansu Yinghaitang Pharmaceutical Co.
, Ltd.
, Gansu Baohe Pharmaceutical Co.
, Ltd.
Traditional Chinese Medicine Piece Factory, Jiuquan Hongyang Traditional Chinese Medicine Announcement on the "Drug Production License" of 10 pharmaceutical companies of Wood Ecological Planting and Processing Co.
,
Ltd.
The main reason for the cancellation is that the "drug production licenses" of these enterprises have expired and have not been renewed
.
The bureau also stated that if the above-mentioned enterprises want to continue drug production activities, they need to raise objections to the provincial bureau within the publicity time
.
On January 10, the Yunnan Provincial Food and Drug Administration issued an announcement on the cancellation of the "Drug Production License" of Yunnan Jigongyuan Biotechnology Co.
,
Ltd.
The announcement shows that the company applied for the cancellation certificate independently and finally produced medicines
.
According to the data, the company's production scope is Chinese herbal medicine
.
On January 4, the Yunnan Provincial Food and Drug Administration announced that Kunming Xuanqing Biotechnology Co.
, Ltd.
applied for the cancellation of the "Drug Production License" and terminated the production of drugs
.
The cancellation of the application complies with the relevant laws and regulations, and after the study of the Yunnan Provincial Food and Drug Administration, the cancellation is approved
.
In addition, in January, companies including Lijiang Huali Biological Development Pharmaceutical Co.
, Ltd.
also voluntarily applied for the cancellation of the "Drug Production License" and terminated the production of drugs
.
According to the regulations, pharmaceutical companies will not be allowed to engage in any form of drug production after canceling the certificate. .
Judging from the fact that a large number of pharmaceutical companies have voluntarily cancelled their certificates, the entire pharmaceutical market is surging, and the reshuffle is intensifying
.